Loriot Y - Search Results

1

Minimal residual disease in solid neoplasia: New frontier or red-herring?

Mordant P, Loriot Y, Lahon B, Castier Y, Lesèche G, Soria JC, Massard C, Deutsch E. Mordant P, et al. Among authors: loriot y. Cancer Treat Rev. 2012 Apr;38(2):101-10. doi: 10.1016/j.ctrv.2011.04.014. Epub 2011 May 25. Cancer Treat Rev. 2012. PMID: 21612875 Review.

2

Drug insight: gastrointestinal and hepatic adverse effects of molecular-targeted agents in cancer therapy.

Loriot Y, Perlemuter G, Malka D, Penault-Llorca F, Boige V, Deutsch E, Massard C, Armand JP, Soria JC. Loriot Y, et al. Nat Clin Pract Oncol. 2008 May;5(5):268-78. doi: 10.1038/ncponc1087. Epub 2008 Mar 18. Nat Clin Pract Oncol. 2008. PMID: 18349858 Review.

3

MVP and vinorelbine for malignant pleural mesothelioma.

Mordant P, Loriot Y, Soria JC, Deutsch E. Mordant P, et al. Among authors: loriot y. Lancet. 2008 Aug 23;372(9639):629; author reply 629-30. doi: 10.1016/S0140-6736(08)61273-8. Lancet. 2008. PMID: 18722865 No abstract available.

4

Antisense oligonucleotide targeting Bcl-2 messenger RNA in cancer: bad drug, bad target, neither or both?

Loriot Y, Mordant P, Deutsch E. Loriot Y, et al. Ann Oncol. 2009 Mar;20(3):596-7; author reply 597. doi: 10.1093/annonc/mdn772. Epub 2009 Jan 22. Ann Oncol. 2009. PMID: 19164457 Free article. No abstract available.

5

Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.

Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Fizazi K. Loriot Y, et al. Ann Oncol. 2009 Apr;20(4):703-8. doi: 10.1093/annonc/mdn694. Epub 2009 Jan 29. Ann Oncol. 2009. PMID: 19179557 Free article.

6

Wound healing delay after central venous access following DCF/VEGF-trap therapy.

Ferté C, Massard C, Moldovan C, Desruennes E, Loriot Y, Soria JC. Ferté C, et al. Among authors: loriot y. Invest New Drugs. 2009 Dec;27(6):583-5. doi: 10.1007/s10637-009-9227-7. Epub 2009 Feb 17. Invest New Drugs. 2009. PMID: 19221694

7

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.

Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, Tournay E, Bouzy J, Laplanche A. Fizazi K, et al. Among authors: loriot y. J Clin Oncol. 2009 May 20;27(15):2429-35. doi: 10.1200/JCO.2008.18.9811. Epub 2009 Apr 13. J Clin Oncol. 2009. PMID: 19364971 Clinical Trial.

8

[Molecular aspects of head and neck, and lung cancer oncogenesis].

Loriot Y, Mordant P, Fouret P, Deutsch E, Soria JC. Loriot Y, et al. Bull Cancer. 2009;96 Suppl 1:S13-24. doi: 10.1684/bdc.2009.0786. Bull Cancer. 2009. PMID: 19433370 Review. French.

9

Reversible cardiogenic shock following 5-fluorouracil infusion.

Ferté C, Gomez Roca C, Loriot Y, Bahleda R, Moldovan C, Cohen A, Izzedine H, Soria JC, Ederhy S. Ferté C, et al. Among authors: loriot y. Invest New Drugs. 2010 Aug;28(4):531-3. doi: 10.1007/s10637-009-9271-3. Epub 2009 Jun 5. Invest New Drugs. 2010. PMID: 19499187

10

Are RAS mutations predictive markers of resistance to standard chemotherapy?

Loriot Y, Mordant P, Deutsch E, Olaussen KA, Soria JC. Loriot Y, et al. Nat Rev Clin Oncol. 2009 Sep;6(9):528-34. doi: 10.1038/nrclinonc.2009.106. Epub 2009 Jul 14. Nat Rev Clin Oncol. 2009. PMID: 19597509 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

309 results

Search Page

Filters